PharmiWeb.com - Global Pharma News & Resources
13-Dec-2018

Anti-CD28 Antibody Pipeline Insight Report 2018 Featuring Alpine Immune Sciences, Janssen Biotech, Bayer HealthCare Pharmaceuticals & Bristol-Myers Squibb - ResearchAndMarkets.com

The "Anti-CD28 Antibody - Pipeline Insight, 2018" drug pipeline has been added to ResearchAndMarkets.com's offering.

'Anti-CD28 Antibody - Pipeline Insight, 2018' report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti-CD28 Antibody development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Descriptive coverage of pipeline development activities for Anti-CD28 Antibody - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Key Topics Covered:

1. Report Introduction

2. Anti-CD28 Antibody - Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for Anti-CD28 Antibody

4. Comparative Analysis

5. Anti-CD28 Antibody Pipeline Products in Clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

6. Anti-CD28 Antibody Pipeline Products in Non-clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment: Active Products

  • Pipeline Assessment by Route of Administration
  • Pipeline Assessment by Stage and Route of Administration
  • Pipeline Assessment by Molecule Type
  • Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

  • Product Description
  • Research and Development
  • Product Development Activities
  • Reason for dormancy/discontinuation

Companies Mentioned

  • Alpine Immune Sciences
  • Janssen Biotech
  • Bayer HealthCare Pharmaceuticals
  • Bristol-Myers Squibb

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/37vqxn/anticd28?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181213005885/en/

Editor Details

Last Updated: 13-Dec-2018